UTHR Valuation

United Therapeutics Corp

Add to Watchlist

Advanced Chart

448.930

-7.91(-1.731%)1D

Overview
Forecast
Valuation
Earnings

UTHR Relative Valuation

UTHR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, UTHR is overvalued; if below, it's undervalued.

Historical Valuation

United Therapeutics Corp (UTHR) is now in the Overvalued zone, suggesting that its current forward PE ratio of 16.19 is considered Overvalued compared with the five-year average of 12.13. The fair price of United Therapeutics Corp (UTHR) is between 305.24 to 384.03 according to relative valuation methord. Compared to the current price of 445.95 USD , United Therapeutics Corp is Overvalued By 16.13%.

Relative Value

Fair Zone

305.24-384.03

Current Price：445.95

16.13%

Overvalued

15.93

Trailing

Forward

9.39

EV/EBITDA

United Therapeutics Corp. (UTHR) has a current EV/EBITDA of 9.39. The 5-year average EV/EBITDA is 6.50. The thresholds are as follows: Strongly Undervalued below 3.76, Undervalued between 3.76 and 5.13, Fairly Valued between 7.87 and 5.13, Overvalued between 7.87 and 9.24, and Strongly Overvalued above 9.24. The current Forward EV/EBITDA of 9.39 falls within the Strongly Overvalued range.

9.48

EV/EBIT

United Therapeutics Corp. (UTHR) has a current EV/EBIT of 9.48. The 5-year average EV/EBIT is 6.52. The thresholds are as follows: Strongly Undervalued below 3.36, Undervalued between 3.36 and 4.94, Fairly Valued between 8.10 and 4.94, Overvalued between 8.10 and 9.68, and Strongly Overvalued above 9.68. The current Forward EV/EBIT of 9.48 falls within the Overvalued range.

6.27

United Therapeutics Corp. (UTHR) has a current PS of 6.27. The 5-year average PS is 4.71. The thresholds are as follows: Strongly Undervalued below 3.59, Undervalued between 3.59 and 4.15, Fairly Valued between 5.27 and 4.15, Overvalued between 5.27 and 5.82, and Strongly Overvalued above 5.82. The current Forward PS of 6.27 falls within the Strongly Overvalued range.

13.02

P/OCF

United Therapeutics Corp. (UTHR) has a current P/OCF of 13.02. The 5-year average P/OCF is 10.16. The thresholds are as follows: Strongly Undervalued below 7.43, Undervalued between 7.43 and 8.80, Fairly Valued between 11.52 and 8.80, Overvalued between 11.52 and 12.88, and Strongly Overvalued above 12.88. The current Forward P/OCF of 13.02 falls within the Strongly Overvalued range.

16.82

P/FCF

United Therapeutics Corp. (UTHR) has a current P/FCF of 16.82. The 5-year average P/FCF is 12.25. The thresholds are as follows: Strongly Undervalued below 8.55, Undervalued between 8.55 and 10.40, Fairly Valued between 14.11 and 10.40, Overvalued between 14.11 and 15.96, and Strongly Overvalued above 15.96. The current Forward P/FCF of 16.82 falls within the Strongly Overvalued range.

United Therapeutics Corp (UTHR) has a current Price-to-Book (P/B) ratio of 2.88. Compared to its 3-year average P/B ratio of 2.23 , the current P/B ratio is approximately 28.95% higher. Relative to its 5-year average P/B ratio of 2.24, the current P/B ratio is about 28.69% higher. United Therapeutics Corp (UTHR) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 6.53%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 6.84% , the current FCF yield is about -100.00% lower.

2.83

P/B

Median3y

2.23

Median5y

2.24

5.18

FCF Yield

Median3y

6.53

Median5y

6.84

Competitors Valuation Multiple

The average P/S ratio for UTHR's competitors is 14.25, providing a benchmark for relative valuation. United Therapeutics Corp Corp (UTHR) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 11.71%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

UTHR.O

United Therapeutics Corp

Ascentage Pharma Group International

24.24

14.99B

Performance Decomposition

Market capitalization of UTHR increased by 22.16% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 714.90M to 798.60M.

The secondary factor is the P/E Change, contributed 10.81%to the performance.

Overall, the performance of UTHR in the past 1 year is driven by Revenue Growth. Which is more sustainable.

11.71%

714.90M → 798.60M

Revenue Growth

-0.36%

38.90 → 38.76

Margin Expansion

10.81%

15.81 → 17.52

P/E Change

22.16%